Pasithea Therapeutics Corp.
KTTA
$0.77
-$0.03-4.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.71M | 7.11M | 6.78M | 6.71M | 7.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.69M | 13.86M | 13.75M | 13.89M | 14.25M |
| Operating Income | -16.69M | -13.86M | -13.75M | -13.89M | -14.25M |
| Income Before Tax | -20.43M | -13.49M | -13.46M | -13.61M | -13.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.43 | -13.49 | -13.46 | -13.61 | -13.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.43M | -13.49M | -13.46M | -13.61M | -13.90M |
| EBIT | -16.69M | -13.86M | -13.75M | -13.89M | -14.25M |
| EBITDA | -16.03M | -13.19M | -13.11M | -13.24M | -13.60M |
| EPS Basic | -3.47 | -5.21 | -7.68 | -10.72 | -12.82 |
| Normalized Basic EPS | -1.96 | -3.26 | -4.80 | -6.70 | -8.01 |
| EPS Diluted | -3.47 | -5.21 | -7.68 | -10.72 | -12.82 |
| Normalized Diluted EPS | -1.96 | -3.26 | -4.80 | -6.70 | -8.01 |
| Average Basic Shares Outstanding | 28.07M | 16.55M | 10.15M | 5.55M | 4.38M |
| Average Diluted Shares Outstanding | 28.07M | 16.55M | 10.15M | 5.55M | 4.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |